The pharmacological management of depression – Update 2017
Depression affects nearly 350 million people worldwide. Local data indicates that approximately 17% of all South Africans will experience at least one episode of depression in their lifetime. Depressive disorders contribute significantly towards overall morbidity and increased risk for suicide. Anti...
Main Authors: | Elzbieta Osuch, Andre Marais |
---|---|
Format: | Article |
Language: | English |
Published: |
AOSIS
2017-03-01
|
Series: | South African Family Practice |
Subjects: | |
Online Access: | https://safpj.co.za/index.php/safpj/article/view/4625 |
Similar Items
-
The Melatonergic System in Mood and Anxiety Disorders and the Role of Agomelatine: Implications for Clinical Practice
by: Domenico De Berardis, et al.
Published: (2013-06-01) -
Monoaminergic System Modulation in Depression and Alzheimer’s Disease: A New Standpoint?
by: Maria Grazia Morgese, et al.
Published: (2019-05-01) -
Brain Neurotransmitter Modulation by Gut Microbiota in Anxiety and Depression
by: Fei Huang, et al.
Published: (2021-03-01) -
Blues in the Brain and Beyond: Molecular Bases of Major Depressive Disorder and Relative Pharmacological and Non-Pharmacological Treatments
by: Elisabetta Maffioletti, et al.
Published: (2020-09-01) -
Neurobiological Bases of the Use of Atypical Antipsychotics in Treatment-Resistant Major Depressive Disorder
by: Kirby, Julia
Published: (2018)